<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592059</url>
  </required_header>
  <id_info>
    <org_study_id>Sece-1</org_study_id>
    <nct_id>NCT00592059</nct_id>
  </id_info>
  <brief_title>Systemic Consolidation Therapy After Chemoradiation Therapy Following Operation for High Risk Early Stage Cervical Cancer</brief_title>
  <official_title>A Phase II Study of Systemic Consolidation Therapy With Paclitaxel Plus Carboplatin Following Radical Hysterectomy and Adjuvant Chemoradiation for High Risk Early Stage Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the therapeutic efficacy and complications of
      systemic consolidation therapy with paclitaxel plus carboplatin following radical
      hysterectomy and adjuvant chemoradiation for high risk early stage cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic consolidation therapy with paclitaxel plus carboplatin (3 cycles per 3 weeks)
      following radical hysterectomy and adjuvant chemoradiation (3 cycles per 3 weeks) for high
      risk early stage cervical cancer will elevate the therapeutic efficacy by removing the
      microscopic metastatic lesions which could not be identified by naked eye and diagnostic
      imaging tests.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Cervical Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who underwent radical hysterectomy for cervical cancer stage IB-IIA

          -  Patients who had at least one of the following risk factors in pathologic results;
             lymph node metastasis, positive residual resection margin, parametrial invasion

          -  above 20 years

          -  GOG performance status 0-2

          -  Informed consent

          -  Platelet&gt;100K, Hb&gt; 10.0 g/dl, ANC&gt;1500/mm3, Cr &lt;1.25*upper normal limit,
             bilirubin&lt;1.5mg/dl, AST &amp; ALT&lt;*3 upper normal limit

          -  Expected life &gt; 6 months

        Exclusion Criteria:

          -  Peripheral neurotoxicity &gt; NCI grade 2

          -  Sever infection

          -  Previous history with chemotherapy or radiation therapy

          -  Pleural effusion, pericardial effusion, and ascites which could cause dyspnea &gt; NCI
             grade 2

          -  Paraaortic lymph node metastasis

          -  Allergy with platinum

          -  Previous history of atrial or ventricular arrhythmia or congestive heart failure

          -  Uncontrolled infection, diabetes mellitus, hypertension, ischemic heart disease,
             myocardiac infarct within 6 months

          -  Severe disease such as acute or chronic renal failure and acute cerebral infarct,
             cerebral hemorrhage, recurrent hepatitis, liver cirrhosis, unknown fever above 39
             degrees centigrade
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Weon Kim, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seung Su Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung Su Han, MD</last_name>
    <phone>082-02-2072-2821</phone>
    <phone_ext>2821</phone_ext>
    <email>hsuu3415@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Su Han, MD</last_name>
      <phone>082-02-2072-2821</phone>
      <phone_ext>2821</phone_ext>
      <email>hsuu3415@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>December 31, 2007</last_update_submitted>
  <last_update_submitted_qc>December 31, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jae Weon Kim</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

